Clinical Response to Low-dose Omalizumab Treatment in Chronic Spontaneous Urticaria: A Retrospective Study of 179 Patients
DOI:
https://doi.org/10.2340/actadv.v103.11627Keywords:
allergy, chronic urticaria, comorbidities, omalizumab, severity, smokingAbstract
Omalizumab is effective in chronic spontaneous urticaria unresponsive to antihistamines. Of the licensed dosing schedules, Korean patients prefer a low dose, of 150 mg/month, for financial reasons. However, real-world experiences of low-dose omalizumab consumption have not been reported. The aim of this retrospective study was to assess the treatment outcomes and long-term clinical course of patients with chronic spontaneous urticaria who were treated with low-dose omalizumab. The study included 179 patients aged ≥ 20 years who were treated with omalizumab 150 mg/month for ≥ 12 weeks. Baseline disease activity was mild, moderate, and severe in 54.7%, 35.2%, and 10.1% of patients, respectively. A complete response was observed in 133 patients at 12 weeks, among whom 88 patients showed early responses within 4 weeks. Overall, 158 patients finally achieved a complete response. Multivariate analyses revealed that baseline disease activity is more likely to be mild in patients who experience early and final complete responses. The absence of atopic comorbidities correlated with an early response. Smoking was associated with a final complete response. This study shows that low-dose omalizumab provides favourable treatment outcomes in antihistamine-refractory chronic spontaneous urticaria. Disease severity, atopic comorbidity, and smoking may be predictive factors for studying the response to omalizumab.
Downloads
References
Kim YS, Park SH, Han K, Bang CH, Lee JH, Park YM. Prevalence and incidence of chronic spontaneous urticaria in the entire Korean adult population. Br J Dermatol 2018; 178: 976-977.
https://doi.org/10.1111/bjd.16105 DOI: https://doi.org/10.1111/bjd.16105
Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022; 77: 734-766.
https://doi.org/10.1111/all.15090 DOI: https://doi.org/10.1111/all.15090
van den Elzen MT, van Os-Medendorp H, van den Brink I, van den Hurk K, Kouznetsova OI, Lokin A, et al. Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria. Clin Transl Allergy 2017; 7: 4.
https://doi.org/10.1186/s13601-017-0141-3 DOI: https://doi.org/10.1186/s13601-017-0141-3
Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 2004; 114: 527-530.
https://doi.org/10.1016/j.jaci.2004.06.032 DOI: https://doi.org/10.1016/j.jaci.2004.06.032
Maurer M, Rosen K, Hsieh HJ, Saini S, Grattan C, Gimenez-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368: 924-935.
https://doi.org/10.1056/NEJMoa1215372 DOI: https://doi.org/10.1056/NEJMoa1215372
Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bulbul Baskan E, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015; 135: 925.
https://doi.org/10.1038/jid.2014.512 DOI: https://doi.org/10.1038/jid.2014.512
Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013; 132: 101-109.
https://doi.org/10.1016/j.jaci.2013.05.013 DOI: https://doi.org/10.1016/j.jaci.2013.05.013
Hide M, Park HS, Igarashi A, Ye YM, Kim TB, Yagami A, et al. Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria. J Dermatol Sci 2017; 87: 70-78.
https://doi.org/10.1016/j.jdermsci.2017.03.009 DOI: https://doi.org/10.1016/j.jdermsci.2017.03.009
Choi JH, Lee DH, Song WJ, Choi M, Kwon JW, Kim GW, et al. The KAAACI/KDA Evidence-Based Practice Guidelines for chronic spontaneous urticaria in Korean adults and children: part 2. management of H1-antihistamine-refractory chronic urticaria. Allergy Asthma Immunol Res 2020; 12: 750-770.
https://doi.org/10.4168/aair.2020.12.5.750 DOI: https://doi.org/10.4168/aair.2020.12.5.750
Metz M, Vadasz Z, Kocaturk E, Gimenez-Arnau AM. Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence. Clin Rev Allergy Immunol 2020; 59: 38-45.
https://doi.org/10.1007/s12016-020-08794-6 DOI: https://doi.org/10.1007/s12016-020-08794-6
Salman A, Ergun T, Gimenez-Arnau AM. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study. J Dermatolog Treat 2020; 31: 204-209.
https://doi.org/10.1080/09546634.2019.1589639 DOI: https://doi.org/10.1080/09546634.2019.1589639
Vadasz Z, Tal Y, Rotem M, Shichter-Confino V, Mahlab-Guri K, Graif Y, et al. Omalizumab for severe chronic spontaneous urticaria: real-life experiences of 280 patients. J Allergy Clin Immunol Pract 2017; 5: 1743-1745.
https://doi.org/10.1016/j.jaip.2017.08.035 DOI: https://doi.org/10.1016/j.jaip.2017.08.035
Marzano AV, Genovese G, Casazza G, Fierro MT, Dapavo P, Crimi N, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. J Eur Acad Dermatol Venereol 2019; 33: 918-924.
https://doi.org/10.1111/jdv.15350 DOI: https://doi.org/10.1111/jdv.15350
Berry R, Hollingsworth P, Lucas M. Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab. Clin Transl Immunol 2019; 8: e01075.
https://doi.org/10.1002/cti2.1075 DOI: https://doi.org/10.1002/cti2.1075
Spertino J, Curto Barredo L, Rozas Munoz E, Figueras Nart I, Gimenez Arnau A, Serra Baldrich E, et al. Algorithm for treatment of chronic spontaneous urticaria with omalizumab. Actas Dermosifiliogr (Engl Ed) 2018; 109: 771-776. DOI: https://doi.org/10.1016/j.adengl.2018.09.011
https://doi.org/10.1016/j.ad.2018.07.005 DOI: https://doi.org/10.1016/j.ad.2018.07.005
Gimenez Arnau AM, Valero Santiago A, Bartra Tomas J, Jauregui Presa I, Labrador Horrillo M, Miquel Miquel FJ, et al. Therapeutic strategy according to differences in response to omalizumab in patients with chronic spontaneous urticaria. J Investig Allergol Clin Immunol 2019; 29: 338-348.
https://doi.org/10.18176/jiaci.0323 DOI: https://doi.org/10.18176/jiaci.0323
Ertas R, Ozyurt K, Atasoy M, Hawro T, Maurer M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy 2018; 73: 705-712.
https://doi.org/10.1111/all.13345 DOI: https://doi.org/10.1111/all.13345
Ghazanfar MN, Holm JG, Thomsen SF. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study. J Eur Acad Dermatol Venereol 2018; 32: 1761-1767.
https://doi.org/10.1111/jdv.15045 DOI: https://doi.org/10.1111/jdv.15045
Hide M, Fukunaga A, Suzuki T, Nakamura N, Kimura M, Sasajima T, et al. Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: a post-marketing surveillance study. Allergol Int 2023; 72: 286-296.
https://doi.org/10.1016/j.alit.2022.09.003 DOI: https://doi.org/10.1016/j.alit.2022.09.003
Ghazanfar MN, Sand C, Thomsen SF. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. Br J Dermatol 2016; 175: 404-406.
https://doi.org/10.1111/bjd.14540 DOI: https://doi.org/10.1111/bjd.14540
Syrigos N, Grapsa D, Zande M, Tziotou M, Syrigou E. Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria. Int J Dermatol 2018; 57: 417-422.
https://doi.org/10.1111/ijd.13935 DOI: https://doi.org/10.1111/ijd.13935
Kaplan A, Ferrer M, Bernstein JA, Antonova E, Trzaskoma B, Raimundo K, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol 2016; 137: 474-481.
https://doi.org/10.1016/j.jaci.2015.08.023 DOI: https://doi.org/10.1016/j.jaci.2015.08.023
Lieberman PL, Umetsu DT, Carrigan GJ, Rahmaoui A. Anaphylactic reactions associated with omalizumab administration: analysis of a case-control study. J Allergy Clin Immunol 2016; 138: 913-915.e2.
https://doi.org/10.1016/j.jaci.2016.03.030 DOI: https://doi.org/10.1016/j.jaci.2016.03.030
Baker DL, Nakamura GR, Lowman HB, Fischer SK. Evaluation of IgE antibodies to omalizumab (Xolair(R)) and their potential correlation to anaphylaxis. AAPS J 2016; 18: 115-123.
https://doi.org/10.1208/s12248-015-9821-x DOI: https://doi.org/10.1208/s12248-015-9821-x
Lapeere H, Baeck M, Stockman A, Sabato V, Grosber M, Moutschen M, et al. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium. J Eur Acad Dermatol Venereol 2020; 34: 127-134.
https://doi.org/10.1111/jdv.15684 DOI: https://doi.org/10.1111/jdv.15684
Maurer M, Eyerich K, Eyerich S, Ferrer M, Gutermuth J, Hartmann K, et al. Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. Int Arch Allergy Immunol 2020; 181: 321-333.
https://doi.org/10.1159/000507218 DOI: https://doi.org/10.1159/000507218
Kulthanan K, Tuchinda P, Likitwattananurak C, Weerasubpong P, Chularojanamontri L. Does omalizumab modify a course of recalcitrant chronic spontaneous urticaria? A retrospective study in Asian patients. J Dermatol 2018; 45: 17-23.
https://doi.org/10.1111/1346-8138.14081 DOI: https://doi.org/10.1111/1346-8138.14081
Altrichter S, Peter HJ, Pisarevskaja D, Metz M, Martus P, Maurer M. IgE mediated autoallergy against thyroid peroxidase - a novel pathomechanism of chronic spontaneous urticaria? PLoS One 2011; 6: e14794.
https://doi.org/10.1371/journal.pone.0014794 DOI: https://doi.org/10.1371/journal.pone.0014794
Asero R, Marzano AV, Ferrucci S, Lorini M, Carbonelli V, Cugno M. Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria. Clin Exp Immunol 2020; 200: 242-249.
https://doi.org/10.1111/cei.13428 DOI: https://doi.org/10.1111/cei.13428
Kolkhir P, Munoz M, Asero R, Ferrer M, Kocaturk E, Metz M, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol 2022; 149: 1819-1831.
https://doi.org/10.1016/j.jaci.2022.04.010 DOI: https://doi.org/10.1016/j.jaci.2022.04.010
Zhao Z, Cai T, Chen H, Chen L, Chen Y, Gao X, et al. Expert consensus on the use of omalizumab in chronic urticaria in China. World Allergy Organ J 2021; 14: 100610.
https://doi.org/10.1016/j.waojou.2021.100610 DOI: https://doi.org/10.1016/j.waojou.2021.100610
McPherson T. Current understanding in pathogenesis of atopic dermatitis. Ind J Dermatol 2016; 61: 649-655.
https://doi.org/10.4103/0019-5154.193674 DOI: https://doi.org/10.4103/0019-5154.193674
Zhou B, Li J, Liu R, Zhu L, Peng C. The role of crosstalk of immune cells in pathogenesis of chronic spontaneous urticaria. Front Immunol 2022; 13: 879754.
https://doi.org/10.3389/fimmu.2022.879754 DOI: https://doi.org/10.3389/fimmu.2022.879754
Lee HC, Hong JB, Chu CY. Chronic idiopathic urticaria in Taiwan: a clinical study of demographics, aggravating factors, laboratory findings, serum autoreactivity and treatment response. J Formos Med Assoc 2011; 110: 175-182.
https://doi.org/10.1016/S0929-6646(11)60028-4 DOI: https://doi.org/10.1016/S0929-6646(11)60028-4
Stockli SS, Bircher AJ. Generalized pruritus in a patient sensitized to tobacco and cannabis. J Dtsch Dermatol Ges 2007; 5: 303-304.
https://doi.org/10.1111/j.1610-0387.2007.06270.x DOI: https://doi.org/10.1111/j.1610-0387.2007.06270.x
Mortaz E, Folkerts G, Engels F, Nijkamp FP, Redegeld FA. Cigarette smoke suppresses in vitro allergic activation of mouse mast cells. Clin Exp Allergy 2009; 39: 679-687.
https://doi.org/10.1111/j.1365-2222.2009.03209.x DOI: https://doi.org/10.1111/j.1365-2222.2009.03209.x
Kim YS, Kim HY, Ahn HS, Sohn TS, Song JY, Lee YB, et al. The association between tobacco smoke and serum immunoglobulin E levels in Korean adults. Intern Med 2017; 56: 2571-2577.
https://doi.org/10.2169/internalmedicine.8737-16 DOI: https://doi.org/10.2169/internalmedicine.8737-16
Linneberg A, Nielsen NH, Madsen F, Frolund L, Dirksen A, Jorgensen T. Smoking and the development of allergic sensitization to aeroallergens in adults: a prospective population-based study. The Copenhagen Allergy Study. Allergy 2001; 56: 328-332.
https://doi.org/10.1034/j.1398-9995.2000.00509.x-i1 DOI: https://doi.org/10.1034/j.1398-9995.2000.00509.x-i1
Kaplan AP, Gimenez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy 2017; 72: 519-533.
https://doi.org/10.1111/all.13083 DOI: https://doi.org/10.1111/all.13083
Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002; 2: 372-377.
https://doi.org/10.1038/nri803 DOI: https://doi.org/10.1038/nri803
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Min Jae Kim, Bo Ri Kim, Sae Hoon Kim, Yoon Seok Chang, Sang Woong Youn
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
